UCB S.A (UCB) | Financial Analysis & Statements
UCB S.A. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
18.2B
Total Liabilities
7.3B
Shareholders Equity
10.9B
Debt to Equity
0.67
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
UCB S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7.7B | 6.2B | 5.3B | 5.5B | 5.8B |
| Cost of Goods Sold | 2.0B | 1.8B | 1.7B | 1.7B | 1.4B |
| Gross Profit | 5.8B | 4.4B | 3.5B | 3.8B | 4.3B |
| Gross Margin % | 74.3% | 71.5% | 67.5% | 69.6% | 75.1% |
| Operating Expenses | |||||
| Research & Development | 1.8B | 1.8B | 1.6B | 1.7B | 1.6B |
| Selling, General & Administrative | 2.7B | 2.3B | 1.8B | 1.7B | 1.6B |
| Other Operating Expenses | 20.0M | -15.0M | 17.0M | 13.0M | 7.0M |
| Total Operating Expenses | 4.6B | 4.1B | 3.5B | 3.4B | 3.2B |
| Operating Income | 2.0B | 846.0M | 633.0M | 701.0M | 1.3B |
| Operating Margin % | 25.9% | 13.8% | 12.1% | 12.7% | 22.9% |
| Non-Operating Items | |||||
| Interest Income | 46.0M | 29.0M | 27.0M | 12.0M | 7.0M |
| Interest Expense | 128.0M | 159.0M | 144.0M | 71.0M | 45.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 1.8B | 1.2B | 441.0M | 511.0M | 1.2B |
| Income Tax | 264.0M | 98.0M | 98.0M | 91.0M | 170.0M |
| Effective Tax Rate % | 14.5% | 8.4% | 22.2% | 17.8% | 13.9% |
| Net Income | 1.6B | 1.1B | 343.0M | 418.0M | 1.1B |
| Net Margin % | 20.1% | 17.3% | 6.5% | 7.6% | 18.3% |
| Key Metrics | |||||
| EBITDA | 2.6B | 2.1B | 1.3B | 1.3B | 1.6B |
| EPS (Basic) | €8.20 | €5.61 | €1.81 | €2.20 | €5.60 |
| EPS (Diluted) | €8.03 | €5.48 | €1.76 | €2.14 | €5.45 |
| Basic Shares Outstanding | 190119000 | 189986000 | 189690000 | 189619000 | 188973000 |
| Diluted Shares Outstanding | 190119000 | 189986000 | 189690000 | 189619000 | 188973000 |
Income Statement Trend
UCB S.A Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 2.3B | 1.6B | 861.0M | 899.0M | 1.3B |
| Short-term Investments | 196.0M | 184.0M | 195.0M | 243.0M | 212.0M |
| Accounts Receivable | 1.3B | 1.0B | 750.0M | 687.0M | 887.0M |
| Inventory | 1.5B | 1.3B | 1.0B | 907.0M | 878.0M |
| Other Current Assets | 1.0M | - | - | -1.0M | - |
| Total Current Assets | 6.1B | 4.8B | 3.4B | 3.3B | 3.7B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.2B | 1.0B | 953.0M | 903.0M | 828.0M |
| Goodwill | 13.6B | 15.0B | 14.7B | 15.5B | 13.5B |
| Intangible Assets | 3.4B | 4.1B | 4.2B | 4.8B | 3.2B |
| Long-term Investments | 18.0M | 41.0M | 31.0M | 28.0M | 9.0M |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 12.1B | 12.6B | 12.1B | 12.6B | 10.5B |
| Total Assets | 18.2B | 17.3B | 15.5B | 15.9B | 14.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 817.0M | 750.0M | 537.0M | 573.0M | 596.0M |
| Short-term Debt | 62.0M | 63.0M | 42.0M | 262.0M | 55.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 4.4B | 3.5B | 2.6B | 3.1B | 2.8B |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.2B | 3.0B | 3.0B | 2.6B | 2.1B |
| Deferred Tax Liabilities | 109.0M | 91.0M | 286.0M | 377.0M | 191.0M |
| Other Non-Current Liabilities | - | 1.0M | - | - | 1.0M |
| Total Non-Current Liabilities | 2.9B | 3.8B | 3.9B | 3.7B | 3.0B |
| Total Liabilities | 7.3B | 7.3B | 6.6B | 6.8B | 5.8B |
| Equity | |||||
| Common Stock | 584.0M | 584.0M | 584.0M | 584.0M | 584.0M |
| Retained Earnings | 8.7B | 7.4B | 6.6B | 6.4B | 6.3B |
| Treasury Stock | 389.0M | 384.0M | 353.0M | 363.0M | 395.0M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 10.9B | 10.0B | 9.0B | 9.1B | 8.4B |
| Key Metrics | |||||
| Total Debt | 2.2B | 3.0B | 3.0B | 2.9B | 2.1B |
| Working Capital | 1.7B | 1.3B | 828.0M | 192.0M | 886.0M |
Balance Sheet Composition
UCB S.A Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.6B | 1.1B | 343.0M | 418.0M | 1.1B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | -10.0M | 2.0M | 17.0M | -20.0M | 12.0M |
| Working Capital Changes | -571.0M | -575.0M | -211.0M | 4.0M | -278.0M |
| Operating Cash Flow | 1.0B | 605.0M | 78.0M | 531.0M | 683.0M |
| Investing Activities | |||||
| Capital Expenditures | -280.0M | -234.0M | -238.0M | -252.0M | -281.0M |
| Acquisitions | -11.0M | 619.0M | -109.0M | -1.2B | 15.0M |
| Investment Purchases | -18.0M | -19.0M | -18.0M | -17.0M | -19.0M |
| Investment Sales | 88.0M | 4.0M | 3.0M | 19.0M | 9.0M |
| Investing Cash Flow | -221.0M | 370.0M | -358.0M | -1.5B | -261.0M |
| Financing Activities | |||||
| Share Repurchases | -121.0M | -162.0M | -40.0M | -42.0M | -60.0M |
| Dividends Paid | -264.0M | -259.0M | -252.0M | -247.0M | -240.0M |
| Debt Issuance | 0 | 572.0M | 597.0M | 1.0B | 0 |
| Debt Repayment | -641.0M | -756.0M | -424.0M | -546.0M | -716.0M |
| Financing Cash Flow | -1.0B | -605.0M | -119.0M | 190.0M | -1.0B |
| Free Cash Flow | 1.8B | 920.0M | 445.0M | 748.0M | 1.1B |
| Net Change in Cash | -222.0M | 370.0M | -399.0M | -740.0M | -594.0M |
Cash Flow Trend
UCB S.A Key Financial Ratios
No financial ratio data available.
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| Argenx SE | 41.4B | 39.84 | 6.59 | 20.15% | 30.50% | 0.64 |
| Onward Medical N.V | 204.4M | - | 2.98 | -80.85% | 72.51% | 24.70 |
| Hyloris | 152.3M | -23.65 | 5.70 | -21.61% | -71.71% | 6.08 |
| European Medical | 20.7M | 11.14 | 1.72 | 16.43% | 3.46% | 154.89 |
Financial data is updated regularly. All figures are in the company's reporting currency.